Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
By Dr. Matthew Watson
Vancouver, Canada, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD).
Excerpt from:
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
Related Post
- Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - January 22nd, 2025
- Nacuity Pharmaceuticals Granted U.S. FDA Fast Track Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa - January 22nd, 2025
- Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology - January 22nd, 2025
- Welcoming Victor Bornsztejn as Senior Vice President of Commercial - January 22nd, 2025
- Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization... - January 22nd, 2025
- Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas - January 22nd, 2025
- Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31,... - January 22nd, 2025
- RS BioTherapeutics Announces Positive Anti-Inflammatory and Anti-Fibrotic Effects of Lead Compound in Human Lung Tissue - January 22nd, 2025
- Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) - January 22nd, 2025
- Pharming Group to convene Extraordinary General Meeting of Shareholders - January 22nd, 2025
- BioAdaptives Announces FINRA Approval of a Dividend for Common Stock Shareholders - January 22nd, 2025
- Sanara MedTech Inc. Expands Executive Leadership Team with New Appointments - January 22nd, 2025
- Sanara MedTech Inc. Announces Exclusive License and Distribution Agreement with, and Minority Investment in, Biomimetic Innovations Ltd - January 22nd, 2025
- Sanara MedTech Inc. Reports Unaudited Preliminary Results for the Fourth Quarter and Full Year 2024 - January 22nd, 2025
- NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director - January 22nd, 2025
- Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO... - January 22nd, 2025
- Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in... - January 22nd, 2025
- Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible... - January 22nd, 2025
- ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI - January 22nd, 2025
- Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care - January 22nd, 2025
- Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference - January 14th, 2025
- VIVUS Shares Progress on Pipeline and Key Program Milestones During the 43rd Annual J.P. Morgan Healthcare Conference 2025 - January 14th, 2025
- Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities - January 14th, 2025
- Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12 - January 14th, 2025
- Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones - January 14th, 2025
- ProMIS Neurosciences Issues Letter to Shareholders - January 14th, 2025
- BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones - January 14th, 2025
- OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer - January 14th, 2025
- Correction: GUERBET : Financial agenda for 2025 - January 14th, 2025
- Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without... - January 14th, 2025
- Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference - January 14th, 2025
- Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference - January 14th, 2025
- Nxera Pharma Provides Update on Neurocrine’s Progress with its Partnered Muscarinic Agonist Portfolio - January 14th, 2025
- FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s... - January 14th, 2025
- Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial - January 14th, 2025
- HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC - January 14th, 2025
- Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference - January 14th, 2025
- Idorsia publishes an invitation to a bondholder meeting - January 14th, 2025
- Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease - January 14th, 2025
- Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy... - January 14th, 2025
- Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
- Tilray Brands Moves Earnings Date to January 10, 2025, in Observance of the National Day of Mourning - January 5th, 2025
- ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab - January 5th, 2025
- SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
- Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin® - January 5th, 2025
- Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - January 5th, 2025
- Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
- Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8 - January 5th, 2025
- Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar - January 5th, 2025
- Energroup Holdings Corp (OTC: ENHD) to Acquire Cocannco Inc. - January 5th, 2025
- VALNEVA Declaration of shares and voting rights: December 31, 2024 - January 5th, 2025
- Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
- Procaps Group Receives Additional Delinquency Letter - January 5th, 2025
- Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - January 5th, 2025
- BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025 - January 5th, 2025
- Rakovina Therapeutics to Connect with Industry Leaders During 43rd Annual J.P. Morgan Healthcare Conference Week - January 5th, 2025
- Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 5th, 2025
- BriaCell Announces Proposed Effective Date of Share Consolidation - January 5th, 2025
- PharmaTher Announces Grant of Stock Options - January 5th, 2025
- Oculis Publishes Notification of Major Changes in Voting Rights - January 5th, 2025
- Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment - December 27th, 2024
- Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market - December 27th, 2024
- Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference - December 27th, 2024
- Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD - December 27th, 2024
- Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis - December 27th, 2024
- Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million - December 27th, 2024
- Abivax Announces a Change to the Composition of its Board of Directors - December 27th, 2024
- Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference - December 27th, 2024
- Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq - December 27th, 2024
- Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca - December 27th, 2024
- Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. - December 27th, 2024
- SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation - December 27th, 2024
- Optinose Announces 1-for-15 Reverse Stock Split - December 27th, 2024
- Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute - December 27th, 2024
- Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing... - December 27th, 2024
- Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in... - December 27th, 2024
- Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives - December 27th, 2024
- Park Ha Biological Technology Co., Ltd. Announces Pricing of $4.8 Million Initial Public Offering - December 27th, 2024
- argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating... - December 27th, 2024
- T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally - December 18th, 2024
Global News Feed
Comments Off on Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial |
December 27th, 2024
This author published 5992 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research